Quantisnow Logo
Dashboard
Subscribe to $AHPA

Avista Public Acquisition Corp. II

$AHPA
00

IPO Year: 2021

Exchange: NASDAQ

Recent Analyst Ratings for Avista Public Acquisition Corp. II

DatePrice TargetRatingAnalyst
See more ratings

Avista Public Acquisition Corp. II Press Releases

Fastest customizable press release news feed in the world

See more

  • OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

    OmniAb, Inc. (NASDAQ:OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) until its spin-off as an independent publicly traded company as of November 1, 2022. As such, OmniAb will not file a Form 10-Q with the U.S. Securities and Exchange Commission (SEC) for the three months ended September 30, 2022; however, its third quarter financial results have been reported on a Form 8K/A that can be found here. Avista Public Acquisition Corp. II (which changed its name to OmniAb, Inc. in connection with the merger) filed a Form 10-Q under the name of Omn

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • OmniAb Announces Completion of Spin-Off and Business Combination

    Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

    First FDA approval of a bispecific antibody discovered using OmniAb technology OmniAb, Inc. is eligible to receive a $25 million milestone upon first commercial sale in the United States Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that Janssen Biotech, Inc. (Janssen) has received approval from the U.S. Food and Drug Administration (FDA) for TECVAYLI™ (teclistamab) for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 discovered and developed by Janssen scientists using OmniAb's OmniRat® antibody discovery technology. Under the terms

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • OmniAb Business Combination Approved by APAC Shareholders

    APAC Shareholder Approval Obtained, Closing Scheduled for November 1, 2022 Ligand "Regular Way" and "Ex-Distribution" and OmniAb "When-Issued" Set to Begin Trading on October 25, 2022 Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced the business combination (Business Combination) of Avista Public Acquisition Corp. II (APAC) (NASDAQ:AHPA) and OmniAb, Inc. (OmniAb), was approved by APAC shareholders in a vote held this morning, with 96% of the shares represented in person, virtually or by proxy voting in favor of the combination. Based on actual redemptions and estimated expenses, OmniAb expects to have approximately $95 million of net cash upon the closing of the Business

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off

    Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of OmniAb, Inc. to be distributed to Ligand shareholders in order to effect the separation of Ligand and OmniAb into two independent, publicly traded companies. The dividend in OmniAb shares is expected to be distributed to Ligand shareholders on or about November 1, 2022, the expected closing date of the previously announced business combination (Business Combination) between OmniAb and Avista Public Acquisition Corp. II (APAC) (NASDAQ:AHPA). Following the closing of the Business Combination, APAC

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business Combination

    Extraordinary General Meeting of APAC Shareholders to Vote on Proposed Business Combination with OmniAb to be Held on October 24, 2022 NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Avista Public Acquisition Corp. II (NASDAQ:AHPA) ("APAC") announced today the effectiveness of the Registration Statement on Form S-4 filed with the Securities and Exchange Commission (the "SEC") in connection with the previously announced business combination (the "Business Combination") between APAC and OmniAb, Inc. ("OmniAb"), a wholly owned subsidiary of Ligand Pharmaceuticals Incorporated ("Ligand"). APAC also announced that the extraordinary general meeting of its shareholders (the "Special Meeting") to approve th

  • Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

    First European Commission approval of a bispecific antibody discovered using OmniAb OmniAb, Inc. is eligible to receive a $10 million milestone upon first commercial sale in Europe Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that the Janssen Biotech, Inc. (Janssen) received conditional marketing authorization (CMA) from the European Commission for TECVAYLI® (teclistamab) as monotherapy for the treatment of patients with relapsed or refractory (R/R) multiple myeloma. Teclistamab is a T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 that was discovered by Janssen scientists using OmniAb's OmniRat antibody discovery technology.

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Ligand Reports Second Quarter 2022 Financial Results

    Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 continues to be an outstanding year for Ligand, in particular as royalties from our Pelican Expression Technology platform grow into meaningful revenue contributors," said John Higgins, CEO of Ligand. "The business is enjoying good momentum with numerous positive late-stage de

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Ligand Reports First Quarter 2022 Financial Results

    Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 is off to a strong start with solid financial performance from our growing roster of royalty-bearing products and great execution from all our core technology platforms," said John Higgins, CEO of Ligand. "We are excited about the potential growth of our business in the years to come as several recently approved pr

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II

    Transaction will result in OmniAb becoming an independent publicly traded company Ligand's shareholders to receive 100% of Ligand's shares in OmniAb through a tax-free distribution immediately prior to the merger Ligand Pharmaceuticals Incorporated (Ligand) (NASDAQ:LGND) today announced the signing of a definitive merger agreement with Avista Public Acquisition Corp. II (APAC) (NASDAQ:AHPA), a publicly traded special purpose acquisition company (SPAC), providing for the spin-off of OmniAb, Inc. (OmniAb), Ligand's antibody discovery business, immediately followed by a merger with a newly formed subsidiary of APAC. The combined company will be led by Ligand's President, Matt Foehr, and will

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

Avista Public Acquisition Corp. II Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

Avista Public Acquisition Corp. II Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

Avista Public Acquisition Corp. II SEC Filings

See more

Avista Public Acquisition Corp. II Leadership Updates

Live Leadership Updates

See more

  • OmniAb Announces Completion of Spin-Off and Business Combination

    Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

Avista Public Acquisition Corp. II Financials

Live finance-specific insights

See more

  • Ligand Reports Second Quarter 2022 Financial Results

    Raises 2022 Financial Guidance Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 continues to be an outstanding year for Ligand, in particular as royalties from our Pelican Expression Technology platform grow into meaningful revenue contributors," said John Higgins, CEO of Ligand. "The business is enjoying good momentum with numerous positive late-stage de

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Ligand Reports First Quarter 2022 Financial Results

    Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2022 is off to a strong start with solid financial performance from our growing roster of royalty-bearing products and great execution from all our core technology platforms," said John Higgins, CEO of Ligand. "We are excited about the potential growth of our business in the years to come as several recently approved pr

    $AHPA
    $LGND
    Biotechnology: Pharmaceutical Preparations
    Health Care

Avista Public Acquisition Corp. II Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more